For any possible anti-virus drug development, the prediction of possible resistant mutations that may emerge during drug-treatments and their hypothetical solutions, would be most important. Although some resistant mutations may have deleterious effects on viral replication, such as demonstrated on human respiratory syncytial virus . Nevertheless, the hundreds of top DW-BEL-and ADV-conformer candidates cross-docking to gpGVHSV R4-TrD, raise the probabilities to find some against possible emergent mutations. Similar coevolution screening attempts were described before on other protein / ligand pairs. For instance, co-evolved children docking to the new mutations in SARS-CoV2 omicron variants , anti-coagulant co-evolved children affecting rat mutants but not humans or screening co-evolved children against Tecovirimat-emergent resistant human monkeypox variants .